Received Aug 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | Y020588 | — |
No additional AE; HCP stated that the vaccine was administered "more in the center of the arm." HCP stated that the GARDASIL 9 vaccine was not administered in the deltoid area.; This spontaneous report was received from a medical assistant and refers to a 13-year-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 18-Aug-2025, the patient was vaccinated with the first dose (in a two dose series) of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (lot #Y020588, expiration date reported as 11-Aug-2027 and upon internal validation confirmed to be 11-Aug-2027) (route of administration was not reported) 0,5 mL administered a little below the deltoid area, about halfway down the arm between shoulder and elbow, more in the center of the arm for prophylaxis (product administered at inappropriate site). The vaccine was not administered in the deltoid area. No symptoms were reported. No additional adverse event (AE) and no product quality complaint (PQC) was reported (no adverse event).